If you have had a diagnosis of ovarian cancer and would like more information about the following treatments, please contact our support line on 020 7923 5475 or speak to your treatment team.
Niraparib (Zejula®)
- England
-
Niraparib (Zejula®) is available to women with newly diagnosed advanced (stage III or IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy. This is currently available through the Cancer Drugs Fund.
- Scotland
-
Women with recurrent ovarian cancer who don't have a BRCA mutation can access niraparib (Zejula®). It is not available to women with a BRCA mutation on the basis that they can access olaparib (Lynparza®).
- Wales
-
Niraparib (Zejula®) is available to women in Wales with newly diagnosed advanced (stage III or IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy on the same basis to the Cancer Drugs Fund in England.
- Northern Ireland
-
Niraparib (Zejula®) is available to women in Northern Ireland with newly diagnosed advanced (stage III or IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy on the same basis to the Cancer Drugs Fund in England.
Bevacizumab (Avastin®)
- England
-
It is approved for use under the Cancer Drugs Fund for women with advanced ovarian cancer as part of first-line treatment.
- Scotland
-
It is approved by the Scottish Medicines Consortium for use in first-line treatment of advanced disease or in platinum-resistant (where platinum-based chemotherapy has stopped working) recurrent disease.
- Wales
-
It is not available in Wales. This is because it was approved under the old Cancer Drugs Fund and while it continues to be made available in England, it doesn't meet the criteria for inclusion under the New Treatment Fund in Wales.
- Northern Ireland
-
It is not available in Northern Ireland.
Olaparib (Lynparza®)
- England
-
Olaparib is currently available to women with a mutation in the BRCA1 or BRCA2 gene as part of third-line treatment onwards. NICE is currently reviewing whether to continue to fund olaparib for this group.
- Scotland
-
Women in Scotland with recurrent ovarian cancer can access olaparib (Lynparza®) if they have a mutation in the BRCA1 or BRCA2 gene.
- Wales
-
Olaparib (Lynparza®) is available to women with a mutation in the BRCA1 or BRCA2 gene as part of third-line treatment onwards. NICE is currently reviewing whether to continue to fund olaparib for this group.
- Northern Ireland
-
Women with a mutation in the BRCA1 or BRCA2 gene can access olaparib as part of third-line treatment onwards. NICE is currently reviewing whether to continue to fund olaparib for this group.
